Pacira (PCRX) reported $179.52 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 7%. EPS of $0.70 for the same period compares to $0.79 a year ago.
The reported revenue represents a surprise of -1.6% over the Zacks Consensus Estimate of $182.44 million. With the consensus EPS estimate being $0.65, the EPS surprise was +7.69%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Pacira performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Net product sales- iovera: $6.47 million compared to the $6.38 million average estimate based on four analysts. The reported number represents a change of +14.3% year over year.
- Revenue- Net product sales- ZILRETTA: $28.98 million compared to the $30.43 million average estimate based on four analysts. The reported number represents a change of +2% year over year.
- Revenue- Net product sales- Bupivacaine liposome injectable suspension: $2.69 million versus the four-analyst average estimate of $1.2 million. The reported number represents a year-over-year change of +63.8%.
- Revenue- Total net product sales: $178.04 million versus $181.63 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +6.2% change.
- Revenue- Net product sales- EXPAREL: $139.9 million compared to the $143.64 million average estimate based on four analysts. The reported number represents a change of +6% year over year.
- Revenue- Royalty revenue: $1.48 million versus $1.08 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +73.4% change.
View all Key Company Metrics for Pacira here>>>
Shares of Pacira have returned -6.7% over the past month versus the Zacks S&P 500 composite's +1.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pacira BioSciences, Inc. (PCRX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
